Interview

Telix Pharmaceuticals (ASX:TLX) has completed the transaction to expand its theranostic pipeline with new candidates targeting Fibroblast Activation Protein (FAP), one of the most promising pan-cancer targets in nuclear medicine.

Argent BioPharma (ASX:RGT) has signed an agreement with Dr Shlomo Sadoun granting him exclusive rights to facilitate a commercial transaction for the company's Malta-based GMP-certified manufacturing facility.

Proteomics International Laboratories (ASX:PIQ) has officially launched its first-in-class predictive test for diabetic kidney disease, PromarkerD, in Australia.

Australian biotechnology company Noxopharm (ASX:NOX) has engaged Doherty Clinical Trials to conduct its upcoming phase 1 HERACLES trial.

Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) has announced that Dr James Campbell will succeed Steven Engle as its chair.

Respiratory imaging technology company 4DMedical (ASX:4DX) has announced the renewal and extension of the contract for its pulmonary function software-as-a-service analysis with the Cleveland Clinic.

PolyNovo (ASX:PNV) has announced that its chief executive officer, Swami Raote, will officially leave the company in June but will step down immediately.

Australian company Anatara Lifesciences (ASX:ANR) has updated investors on the GaRP-Irritable Bowel Syndrome phase 2 trial and the anti-obesity project.

Medtech entrepreneurs are invited to showcase their innovations at the 2025 Early-Stage Innovation Forum (ESIF), a premier platform for emerging developers to present their cutting-edge solutions at the AusMedtech 2025 conference in Sydney 6 – 8 May.

Clinical-stage biotechnology company Vaxxas has announced the publication of data supporting the potential use of its high-density microarray patch technology to deliver nucleic acid-based vaccines in collaboration with The University of Queensland and Technovalia.

Australian company Atmo Biosciences has announced the publication of pivotal clinical study data in Clinical Gastroenterology and Hepatology.

The George Institute for Global Health, a leading medical research organisation, has appointed Dr Paul Schreier as its new board chair.